Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)

M. Imbimbo, M. Ottaviano, M. Vitali, A. Fabbri, G. Leuzzi, M. Fiore, D. Franceschini, G. Pasello, M. Perrino, M. Schiavon, G. Pruneri, A.P. Dei Tos, C. Sangalli, M.C. Garassino, R. Berardi, A. Alessi, G. Calareso, I. Petrini, M. Scorsetti, V. Scotti & 13 others L. Rosso, F. Rea, U. Pastorino, P.G. Casali, S. Ramella, U. Ricardi, L. Abate-Daga, V. Torri, A. Trama, G. Palmieri, M. Marino, P.A. Zucali, TYME network collaborators

Research output: Contribution to journalArticle

Abstract

Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system. © 2018 Elsevier Ltd
Original languageEnglish
Pages (from-to)76-87
Number of pages12
JournalCancer Treatment Reviews
Volume71
DOIs
Publication statusPublished - Dec 2018

Fingerprint

Practice Management
Practice Guidelines
Neoplasms
Neoplasm Staging
Italy
Guidelines
Patient Advocacy
Expert Testimony
Thymic epithelial tumor
Thorax
Research

Keywords

  • avelumab
  • capecitabine
  • carboplatin
  • cisplatin
  • cyclophosphamide
  • doxorubicin
  • etoposide
  • fluorouracil
  • gemcitabine
  • ifosfamide
  • imatinib
  • nivolumab
  • octreotide
  • paclitaxel
  • pembrolizumab
  • pemetrexed
  • prednisone
  • ramucirumab
  • sunitinib
  • contrast medium, cancer radiotherapy
  • cancer staging
  • clinical practice
  • epithelium tumor
  • health care
  • health center
  • human
  • Italy
  • medical expert
  • minimally invasive surgery
  • multidisciplinary team
  • phase 2 clinical trial (topic)
  • practice guideline
  • Review
  • thymoma
  • total quality management
  • adjuvant chemotherapy
  • autoimmune disease
  • diagnostic imaging
  • female
  • male
  • neoplasm
  • pathology
  • procedures
  • tumor recurrence
  • x-ray computed tomography, Autoimmune Diseases
  • Chemotherapy, Adjuvant
  • Contrast Media
  • Female
  • Humans
  • Male
  • Neoplasm Recurrence, Local
  • Neoplasms, Glandular and Epithelial
  • Thymus Neoplasms
  • Tomography, X-Ray Computed

Cite this

@article{f12055beaea64ea3898cf406472c8161,
title = "Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)",
abstract = "Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system. {\circledC} 2018 Elsevier Ltd",
keywords = "avelumab, capecitabine, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, fluorouracil, gemcitabine, ifosfamide, imatinib, nivolumab, octreotide, paclitaxel, pembrolizumab, pemetrexed, prednisone, ramucirumab, sunitinib, contrast medium, cancer radiotherapy, cancer staging, clinical practice, epithelium tumor, health care, health center, human, Italy, medical expert, minimally invasive surgery, multidisciplinary team, phase 2 clinical trial (topic), practice guideline, Review, thymoma, total quality management, adjuvant chemotherapy, autoimmune disease, diagnostic imaging, female, male, neoplasm, pathology, procedures, tumor recurrence, x-ray computed tomography, Autoimmune Diseases, Chemotherapy, Adjuvant, Contrast Media, Female, Humans, Male, Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Thymus Neoplasms, Tomography, X-Ray Computed",
author = "M. Imbimbo and M. Ottaviano and M. Vitali and A. Fabbri and G. Leuzzi and M. Fiore and D. Franceschini and G. Pasello and M. Perrino and M. Schiavon and G. Pruneri and {Dei Tos}, A.P. and C. Sangalli and M.C. Garassino and R. Berardi and A. Alessi and G. Calareso and I. Petrini and M. Scorsetti and V. Scotti and L. Rosso and F. Rea and U. Pastorino and P.G. Casali and S. Ramella and U. Ricardi and L. Abate-Daga and V. Torri and A. Trama and G. Palmieri and M. Marino and P.A. Zucali and collaborators, {TYME network}",
note = "cited By 0",
year = "2018",
month = "12",
doi = "10.1016/j.ctrv.2018.10.001",
language = "English",
volume = "71",
pages = "76--87",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)

AU - Imbimbo, M.

AU - Ottaviano, M.

AU - Vitali, M.

AU - Fabbri, A.

AU - Leuzzi, G.

AU - Fiore, M.

AU - Franceschini, D.

AU - Pasello, G.

AU - Perrino, M.

AU - Schiavon, M.

AU - Pruneri, G.

AU - Dei Tos, A.P.

AU - Sangalli, C.

AU - Garassino, M.C.

AU - Berardi, R.

AU - Alessi, A.

AU - Calareso, G.

AU - Petrini, I.

AU - Scorsetti, M.

AU - Scotti, V.

AU - Rosso, L.

AU - Rea, F.

AU - Pastorino, U.

AU - Casali, P.G.

AU - Ramella, S.

AU - Ricardi, U.

AU - Abate-Daga, L.

AU - Torri, V.

AU - Trama, A.

AU - Palmieri, G.

AU - Marino, M.

AU - Zucali, P.A.

AU - collaborators, TYME network

N1 - cited By 0

PY - 2018/12

Y1 - 2018/12

N2 - Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system. © 2018 Elsevier Ltd

AB - Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system. © 2018 Elsevier Ltd

KW - avelumab

KW - capecitabine

KW - carboplatin

KW - cisplatin

KW - cyclophosphamide

KW - doxorubicin

KW - etoposide

KW - fluorouracil

KW - gemcitabine

KW - ifosfamide

KW - imatinib

KW - nivolumab

KW - octreotide

KW - paclitaxel

KW - pembrolizumab

KW - pemetrexed

KW - prednisone

KW - ramucirumab

KW - sunitinib

KW - contrast medium, cancer radiotherapy

KW - cancer staging

KW - clinical practice

KW - epithelium tumor

KW - health care

KW - health center

KW - human

KW - Italy

KW - medical expert

KW - minimally invasive surgery

KW - multidisciplinary team

KW - phase 2 clinical trial (topic)

KW - practice guideline

KW - Review

KW - thymoma

KW - total quality management

KW - adjuvant chemotherapy

KW - autoimmune disease

KW - diagnostic imaging

KW - female

KW - male

KW - neoplasm

KW - pathology

KW - procedures

KW - tumor recurrence

KW - x-ray computed tomography, Autoimmune Diseases

KW - Chemotherapy, Adjuvant

KW - Contrast Media

KW - Female

KW - Humans

KW - Male

KW - Neoplasm Recurrence, Local

KW - Neoplasms, Glandular and Epithelial

KW - Thymus Neoplasms

KW - Tomography, X-Ray Computed

U2 - 10.1016/j.ctrv.2018.10.001

DO - 10.1016/j.ctrv.2018.10.001

M3 - Article

VL - 71

SP - 76

EP - 87

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -